Nama's AI scorecard currently rates Boston Scientific Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is BSX's P/E ratio?

Boston Scientific trades at a trailing price-to-earnings ratio of 13.4.

When does BSX report earnings?

Boston Scientific's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $0.78.

What is the BSX price target?

The median analyst price target from 28 analysts is $49.00, with a range of $41.00 – $60.00.

Is BSX Shariah compliant?

Nama's AAOIFI-style screen reads Boston Scientific as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Boston Scientific (BSX)

Healthcare · Medical Devices · NYSE

S&P 500

Boston Scientific (BSX) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $61.96B, a trailing price-to-earnings ratio of 13.4 and a free-cash-flow yield of 5.3%. Over the most recent reported fiscal year, revenue grew 19.9% and free cash flow per share grew 43.1%. Nama's AI scorecard rates it Buy, 6.5 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 6.5/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -58.0% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-61.0%

How far the last close sits under the highest price of the past five years.

Market cap	$61.96B
Trailing P/E	13.4
Price / book	2.5
Price / sales	2.9
FCF yield	5.3%
Dividend yield	—
Gross margin	69.9%
Operating margin	21.0%
Net margin	17.5%
Revenue growth (YoY)	+19.9%
Revenue growth (3-yr annual)	+16.5%
EPS growth (YoY)	+21.5%
FCF/share growth (YoY)	+43.1%
Beta	0.6
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

BSX earnings

Next report: Feb 10, 2027 (Q4 2026, EPS estimate $0.78). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 28, 2026	$0.73	$0.72	+1.4%	$5.14B
Q2 2026	Jul 29, 2026	$0.86	$0.83	+3.6%	$5.44B
Q1 2026	Apr 22, 2026	$0.80	$0.79	+1.3%	$5.20B
Q4 2025	Feb 4, 2026	$0.80	$0.78	+2.6%	$5.29B

BSX analyst price target

Median target $49.00 from 28 analysts, ranging $41.00 – $60.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7
STE	STERIS	$24.60B	23.2

Explore live BSX data on Nama Insights →

Recent Congressional trades

Boston Scientific trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Kevin Hern	House	Sell	$50,001 - $100,000	Sep 25, 2026
Kevin Hern	House	Sell	$50,001 - $100,000	Sep 25, 2026
Kevin Hern	House	Sell	$1,001 - $15,000	Sep 25, 2026
Kevin Hern	House	Sell	$15,001 - $50,000	Sep 25, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 10, 2026
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
John Boozman	Senate	Sell	$1,001 - $15,000	Jul 13, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jul 2, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Mar 9, 2026

BSX FAQ

Is BSX a buy?: Nama's AI scorecard currently rates Boston Scientific Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BSX's P/E ratio?: Boston Scientific trades at a trailing price-to-earnings ratio of 13.4.
When does BSX report earnings?: Boston Scientific's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $0.78.
What is the BSX price target?: The median analyst price target from 28 analysts is $49.00, with a range of $41.00 – $60.00.
Is BSX Shariah compliant?: Nama's AAOIFI-style screen reads Boston Scientific as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.